A newly approved drug that has been hailed as a breakthrough treatment for high cholesterol is causing sticker stock across the healthcare industry.

The injectable treatment, Praluent, is the first of a powerful new class of drugs proven to lower cholesterol. It also carries a list price of $14,600 a year — nearly twice what analysts had been expecting.

“Breakthrough treatments such as Praluent hold tremendous medical promise for certain patients, but its price tag makes us question how long the health system can sustain these costs for patients managing chronic conditions over several years,” John Rother, president of the National Coalition on Health Care, said in a statement.

[button title=”Read More” link=”http://thehill.com/policy/healthcare/249158-fda-approves-cholesterol-drug-with-15000-yearly-price-tag” target=”_blank” size=”” color=”” class=””]